Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Editorial
. 2017 Dec;28(12):3429-3432.
doi: 10.1681/ASN.2017080850. Epub 2017 Oct 20.

Obesity-Related CKD: When Kidneys Get the Munchies

Peter F Mount  1   2   3 , Luis A Juncos  4   5
Affiliations
Editorial

Obesity-Related CKD: When Kidneys Get the Munchies

Peter F Mount et al. J Am Soc Nephrol. 2017 Dec.
No abstract available

Keywords: cannabinoids; lipotoxicity; obesity-induced renal disease; renal fibrosis.

PubMed Disclaimer

Figures

Figure 1.
Figure 1.
eCB pathways involved in obesity-/HFD-associated CKD. Obesity/HFD upregulates the eCB tone via CB1R and CB2R found in the brain/central nervous system (CNS), peripheral tissues, and various cells of the kidneys. In the renal PTCs, obesity-induced lipotoxicity is modulated by the CB1R-coupled α-subunit of heterotrimeric Gi/o protein (Gαi/o)-protein kinase A (PKA) axis, which mediates the downstream activation of the liver kinase B1 (LKB1)/AMPK/ACC signaling pathway; this decreases fatty acid β-oxidation and increases inflammation and fibrosis, resulting in CKD. The CB1R in the peripheral tissues increases hepatic de novo fatty acid synthesis and obesity-induced metabolic and hormonal abnormalities, whereas the CB1R in the brain increases appetite, leptin, obesity, and insulin resistance, which contribute to the development of CKD. Although the CB2R is found in all of these tissues, its role is still unclear. The pathway discussed by Udi et al. in this issue of the Journal of the American Society of Nephrology has been highlighted in yellow. ACC, acetyl-CoA carboxylase; AMPK, AMP-activated protein kinase; eCB, endocannabinoid.
See this image and copyright information in PMC

Comment on

References

    1. Wang Y, Chen X, Song Y, Caballero B, Cheskin LJ: Association between obesity and kidney disease: A systematic review and meta-analysis. Kidney Int 73: 19–33, 2008 - PubMed
    1. Bonnet F, Deprele C, Sassolas A, Moulin P, Alamartine E, Berthezène F, Berthoux F: Excessive body weight as a new independent risk factor for clinical and pathological progression in primary IgA nephritis. Am J Kidney Dis 37: 720–727, 2001 - PubMed
    1. Kambham N, Markowitz GS, Valeri AM, Lin J, D’Agati VD: Obesity-related glomerulopathy: An emerging epidemic. Kidney Int 59: 1498–1509, 2001 - PubMed
    1. Foster MC, Hwang SJ, Porter SA, Massaro JM, Hoffmann U, Fox CS: Fatty kidney, hypertension, and chronic kidney disease: The Framingham Heart study. Hypertension 58: 784–790, 2011 - PMC - PubMed
    1. Kramer H: Kidney disease and the westernization and industrialization of food. Am J Kidney Dis 70: 111–121, 2017 - PubMed